CLYM
Climb Bio, Inc.
Price Chart
Latest Quote
$11.45
+0.11 (+0.97%)
Current Price
| Previous Close | $11.34 |
| Open | $11.69 |
| Day High | $12.18 |
| Day Low | $11.09 |
| Volume | 1,056,362 |
Stock Information
| Shares Outstanding | 57.26M |
| Total Debt | $479K |
| Cash Equivalents | $109.56M |
| Net Income | $-52.79M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $655.66M |
| EPS (TTM) | $-0.77 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $504.18M |
| Income | $-52.79M |
| Book/sh | $3.10 |
| Cash/sh | $1.91 |
| Employees | 28 |
Financial Ratios
| Quick Ratio | 26.91 |
| Current Ratio | 27.86 |
| Debt/Eq | 0.32 |
Returns & Margins
| ROA | -21.27% |
| ROE | -30.92% |
Ownership
| Insider Ownership | 0.37% |
| Institutional Ownership | 66.45% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -10.20 |
| P/B | 3.69 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $20.93 |
Technical Indicators
| SMA20 | $11.13 |
| SMA50 | $10.33 |
| SMA200 | $5.51 |
| RSI | 53.98 |
| ATR | 1.0643 |
| Shares Float | 33.73M |
| Short Float | 4.71% |
| Short Ratio | 2.19 |
| Volatility | 0.10 |
| Rel Volume | 1.02 |
Performance History
| Week | +4.95% |
| Month | +18.65% |
| Quarter | +64.04% |
| 6 Months | +147.84% |
| YTD | +205.33% |
| Year | +854.17% |
| 3 Years | +301.75% |
| 10 Years | -27.99% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $11.45 | 1,246,900 |
| 2026-06-17 | $11.34 | 906,900 |
| 2026-06-16 | $10.71 | 864,600 |
| 2026-06-15 | $11.49 | 1,174,900 |
| 2026-06-12 | $11.44 | 858,900 |
| 2026-06-11 | $10.91 | 1,112,200 |
| 2026-06-10 | $10.80 | 587,500 |
| 2026-06-09 | $11.14 | 3,678,400 |
| 2026-06-08 | $10.77 | 2,228,400 |
| 2026-06-05 | $10.55 | 985,600 |
| 2026-06-04 | $10.91 | 1,210,700 |
| 2026-06-03 | $10.44 | 1,299,800 |
| 2026-06-02 | $11.20 | 1,424,700 |
| 2026-06-01 | $11.80 | 2,481,900 |
| 2026-05-29 | $10.96 | 605,300 |
| 2026-05-28 | $11.34 | 929,100 |
| 2026-05-27 | $11.96 | 1,029,700 |
| 2026-05-26 | $11.39 | 676,300 |
| 2026-05-22 | $11.00 | 454,100 |
| 2026-05-21 | $10.91 | 604,100 |
| 2026-05-20 | $10.52 | 697,400 |
| 2026-05-19 | $9.65 | 516,100 |
About Climb Bio, Inc.
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
đ° Latest News
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect
MarketBeat âĸ 2026-05-21T05:02:30Z
Climb Bio Spotlights Budoprutug CD19 Strategy, Sets Up 2026 Data Readouts in pMN, ITP and SLE
MarketBeat âĸ 2026-05-05T19:27:19Z
Climb Bio (CLYM) Enters Agreement for $110M Private Placement Financing
Insider Monkey âĸ 2026-05-05T17:05:37Z
Why Climb Bio (CLYM) is One of the Best Performing Small Cap Stocks So Far in 2026
Insider Monkey âĸ 2026-05-01T08:17:43Z
Climb Bio (CLYM) Receives FDA Fast Track Designation for Budoprutug in Rare Kidney Disease
Insider Monkey âĸ 2026-04-29T17:00:06Z
FDA Fast Track and a BTIG Buy; Is Climb Bio (CLYM) a Must-Buy Small Cap Stock?
Insider Monkey âĸ 2026-04-20T14:48:52Z
Climb Bio Highlights Budoprutug and CLYM116 Milestones, Sets Up âRich Data Yearâ in 2026
MarketBeat âĸ 2026-03-14T12:03:50Z
Climb Bio Highlights 2025 Data Catalysts, CD19 and APRIL Programs at Oppenheimer Conference
MarketBeat âĸ 2026-02-26T07:11:25Z
Climb Bio Teases 5 Data Readouts in 2026, Highlights CD19 and APRIL âSweeperâ Programs at Summit
MarketBeat âĸ 2026-02-13T08:07:14Z
Climb Bio, Inc. (NASDAQ:CLYM) Shares Could Be 45% Below Their Intrinsic Value Estimate
Simply Wall St. âĸ 2026-01-24T14:18:53Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $67,883,000 | $30,361,000 | $40,275,000 | $45,135,000 |
| Other Income Expense | $-291,000 | $-51,668,000 | $536,000 | $-1,484,000 |
| Net Non Operating Interest Income Expense | $8,323,000 | $8,132,000 | $4,620,000 | $1,375,000 |
| Operating Expense | $67,883,000 | $30,361,000 | $40,275,000 | $45,135,000 |
| General And Administrative Expense | $21,170,000 | $16,025,000 | $24,864,000 | $18,921,000 |
| Other Non Operating Income Expenses | - | - | - | $1,375,000 |
| Other Operating Expenses | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-59,851,000 | $-73,897,000 | $-35,119,000 | $-45,244,000 |
| Net Interest Income | $8,323,000 | $8,132,000 | $4,620,000 | $1,375,000 |
| Interest Income | $8,323,000 | $8,132,000 | $4,620,000 | $1,375,000 |
| Normalized Income | $-59,560,000 | $-22,229,000 | $-35,655,000 | $-43,760,000 |
| Net Income From Continuing And Discontinued Operation | $-59,851,000 | $-73,897,000 | $-35,119,000 | $-45,244,000 |
| Total Operating Income As Reported | $-67,883,000 | $-82,020,000 | $-40,275,000 | $-45,135,000 |
| Net Income Common Stockholders | $-59,851,000 | $-73,897,000 | $-35,119,000 | $-45,244,000 |
| Net Income | $-59,851,000 | $-73,897,000 | $-35,119,000 | $-45,244,000 |
| Net Income Including Noncontrolling Interests | $-59,851,000 | $-73,897,000 | $-35,119,000 | $-45,244,000 |
| Net Income Continuous Operations | $-59,851,000 | $-73,897,000 | $-35,119,000 | $-45,244,000 |
| Pretax Income | $-59,851,000 | $-73,897,000 | $-35,119,000 | $-45,244,000 |
| Special Income Charges | $0 | $-51,659,000 | $0 | - |
| Interest Income Non Operating | $8,323,000 | $8,132,000 | $4,620,000 | $1,375,000 |
| Operating Income | $-67,883,000 | $-30,361,000 | $-40,275,000 | $-45,135,000 |
| Per Share | ||||
| Diluted EPS | $-0.88 | $-1.53 | $-1.30 | $-1.72 |
| Basic EPS | $-0.88 | $-1.53 | $-1.30 | $-1.72 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-67,495,000 | $21,307,000 | $-40,811,000 | $-43,651,000 |
| Total Unusual Items | $-291,000 | $-51,668,000 | $536,000 | $-1,484,000 |
| Total Unusual Items Excluding Goodwill | $-291,000 | $-51,668,000 | $536,000 | $-1,484,000 |
| Reconciled Depreciation | $97,000 | $0 | - | - |
| EBITDA (Bullshit earnings) | $-67,786,000 | $-30,361,000 | $-40,275,000 | $-45,135,000 |
| EBIT | $-67,883,000 | $-30,361,000 | $-40,275,000 | $-45,135,000 |
| Diluted Average Shares | $47,766,338 | $48,298,693 | $26,987,122 | $26,311,554 |
| Basic Average Shares | $47,766,338 | $48,298,693 | $26,987,122 | $26,311,554 |
| Diluted NI Availto Com Stockholders | $-59,851,000 | $-73,897,000 | $-35,119,000 | $-45,244,000 |
| Gain On Sale Of Security | $-291,000 | $-9,000 | $536,000 | $-1,484,000 |
| Research And Development | $46,713,000 | $14,336,000 | $15,411,000 | $26,214,000 |
| Selling General And Administration | $21,170,000 | $16,025,000 | $24,864,000 | $18,921,000 |
| Other Gand A | $21,170,000 | $16,025,000 | $24,864,000 | $18,921,000 |
| Other Special Charges | - | $51,659,000 | - | - |
| Otherunder Preferred Stock Dividend | - | - | - | $0 |
Fetched: 2026-06-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $160,475,000 | $211,881,000 | $107,599,000 | $128,715,000 |
| Total Assets | $167,744,000 | $217,187,000 | $110,469,000 | $134,992,000 |
| Total Non Current Assets | $61,895,000 | $62,315,000 | $214,000 | $599,000 |
| Other Non Current Assets | $1,530,000 | $16,000 | $15,000 | $128,000 |
| Investmentin Financial Assets | $59,572,000 | $61,610,000 | $0 | $0 |
| Current Assets | $105,849,000 | $154,872,000 | $110,255,000 | $134,393,000 |
| Prepaid Assets | $4,769,000 | $3,953,000 | $881,000 | $1,330,000 |
| Cash Cash Equivalents And Short Term Investments | $101,080,000 | $150,919,000 | $106,798,000 | $123,566,000 |
| Cash And Cash Equivalents | $35,685,000 | $87,229,000 | $93,112,000 | $43,585,000 |
| Cash Equivalents | $35,685,000 | $87,229,000 | $93,112,000 | $43,585,000 |
| Other Current Assets | - | $256,000 | $112,000 | $3,005,000 |
| Receivables | - | $1,119,000 | $2,464,000 | $6,492,000 |
| Taxes Receivable | - | $0 | $2,024,000 | $6,492,000 |
| Accrued Interest Receivable | - | $1,119,000 | $440,000 | - |
| Cash Financial | - | - | - | - |
| Debt | ||||
| Total Debt | $541,000 | $532,000 | $349,000 | $480,000 |
| Long Term Debt And Capital Lease Obligation | $285,000 | $375,000 | $15,000 | $180,000 |
| Current Debt And Capital Lease Obligation | $256,000 | $157,000 | $334,000 | $300,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $7,269,000 | $5,306,000 | $2,870,000 | $6,277,000 |
| Total Non Current Liabilities Net Minority Interest | $285,000 | $375,000 | $37,000 | $180,000 |
| Current Liabilities | $6,984,000 | $4,931,000 | $2,833,000 | $6,097,000 |
| Other Current Liabilities | $59,000 | $89,000 | $138,000 | - |
| Payables And Accrued Expenses | $6,669,000 | $4,685,000 | $2,361,000 | $5,797,000 |
| Payables | $2,269,000 | $705,000 | $66,000 | $750,000 |
| Accounts Payable | $2,269,000 | $705,000 | $66,000 | $750,000 |
| Other Non Current Liabilities | - | - | $22,000 | - |
| Equity | ||||
| Common Stock Equity | $160,475,000 | $211,881,000 | $107,599,000 | $128,715,000 |
| Total Equity Gross Minority Interest | $160,475,000 | $211,881,000 | $107,599,000 | $128,715,000 |
| Stockholders Equity | $160,475,000 | $211,881,000 | $107,599,000 | $128,715,000 |
| Gains Losses Not Affecting Retained Earnings | $435,000 | $23,000 | $-2,000 | $-358,000 |
| Other Equity Adjustments | $435,000 | $23,000 | $-2,000 | $-358,000 |
| Retained Earnings | $-289,727,000 | $-229,876,000 | $-155,979,000 | $-120,860,000 |
| Other | ||||
| Ordinary Shares Number | $47,766,338 | $67,255,434 | $27,699,446 | $26,567,681 |
| Share Issued | $47,766,338 | $67,255,434 | $27,699,446 | $26,567,681 |
| Tangible Book Value | $160,475,000 | $211,881,000 | $107,599,000 | $128,715,000 |
| Invested Capital | $160,475,000 | $211,881,000 | $107,599,000 | $128,715,000 |
| Working Capital | $98,865,000 | $149,941,000 | $107,422,000 | $128,296,000 |
| Capital Lease Obligations | $541,000 | $532,000 | $349,000 | $480,000 |
| Total Capitalization | $160,475,000 | $211,881,000 | $107,599,000 | $128,715,000 |
| Additional Paid In Capital | $449,762,000 | $441,727,000 | $263,577,000 | $249,930,000 |
| Capital Stock | $5,000 | $7,000 | $3,000 | $3,000 |
| Common Stock | $5,000 | $7,000 | $3,000 | $3,000 |
| Long Term Capital Lease Obligation | $285,000 | $375,000 | $15,000 | $180,000 |
| Current Capital Lease Obligation | $256,000 | $157,000 | $334,000 | $300,000 |
| Current Accrued Expenses | $4,400,000 | $3,980,000 | $2,295,000 | $5,047,000 |
| Investments And Advances | $59,572,000 | $61,610,000 | $0 | $0 |
| Available For Sale Securities | $59,572,000 | $61,610,000 | - | - |
| Net PPE | $793,000 | $689,000 | $199,000 | $471,000 |
| Gross PPE | $793,000 | $689,000 | $199,000 | $471,000 |
| Other Properties | $793,000 | $689,000 | $199,000 | $471,000 |
| Other Short Term Investments | $65,395,000 | $63,690,000 | $13,686,000 | $79,981,000 |
| Preferred Stock | - | - | - | - |
| Dueto Related Parties Current | - | - | - | - |
Fetched: 2026-06-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-54,542,000 | $-15,562,000 | $-20,599,000 | $-37,369,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-54,356,000 | $-15,562,000 | $-20,599,000 | $-37,369,000 |
| Cash Flow From Continuing Operating Activities | $-54,356,000 | $-15,562,000 | $-20,599,000 | $-37,369,000 |
| Operating Gains Losses | $18,000 | $-42,000 | $-304,000 | $408,000 |
| Investing Activities | ||||
| Capital Expenditure | $-186,000 | - | - | - |
| Investing Cash Flow | $2,833,000 | $-121,092,000 | $68,981,000 | $34,440,000 |
| Cash Flow From Continuing Investing Activities | $2,833,000 | $-121,092,000 | $68,981,000 | $34,440,000 |
| Net Other Investing Changes | - | $-9,645,000 | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $119,750,000 | $0 | $0 |
| Financing Cash Flow | $-21,000 | $130,729,000 | $841,000 | $0 |
| Cash Flow From Continuing Financing Activities | $-21,000 | $130,729,000 | $841,000 | $0 |
| Net Other Financing Charges | $-86,000 | - | - | - |
| Net Common Stock Issuance | $0 | $119,750,000 | $0 | $0 |
| Common Stock Issuance | $0 | $119,750,000 | $0 | $0 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| End Cash Position | $35,685,000 | $87,229,000 | $93,112,000 | $43,585,000 |
| Beginning Cash Position | $87,229,000 | $93,112,000 | $43,585,000 | $46,922,000 |
| Effect Of Exchange Rate Changes | $0 | $42,000 | $304,000 | $-408,000 |
| Changes In Cash | $-51,544,000 | $-5,925,000 | $49,223,000 | $-2,929,000 |
| Proceeds From Stock Option Exercised | $65,000 | $10,979,000 | $841,000 | $0 |
| Net Investment Purchase And Sale | $3,019,000 | $-111,447,000 | $68,981,000 | $34,440,000 |
| Sale Of Investment | $111,097,000 | $20,750,000 | $127,430,000 | $122,403,000 |
| Purchase Of Investment | $-108,078,000 | $-132,197,000 | $-58,449,000 | $-87,963,000 |
| Net PPE Purchase And Sale | $-186,000 | $0 | - | - |
| Purchase Of PPE | $-186,000 | $0 | - | - |
| Change In Working Capital | $-601,000 | $1,698,000 | $3,764,000 | $210,000 |
| Change In Other Current Liabilities | $-207,000 | $-349,000 | $-422,000 | $-447,000 |
| Change In Other Current Assets | $-1,514,000 | $-200,000 | $115,000 | $-60,000 |
| Change In Payables And Accrued Expense | $1,936,000 | $305,000 | $-3,299,000 | $-228,000 |
| Change In Accrued Expense | $372,000 | $1,445,000 | $-2,613,000 | $425,000 |
| Change In Payable | $1,564,000 | $-1,140,000 | $-686,000 | $-653,000 |
| Change In Account Payable | $1,564,000 | $-1,140,000 | $-686,000 | $-653,000 |
| Change In Prepaid Assets | $-816,000 | $1,942,000 | $7,370,000 | $945,000 |
| Other Non Cash Items | $201,000 | $51,879,000 | $405,000 | $443,000 |
| Stock Based Compensation | $8,054,000 | $5,557,000 | $12,806,000 | $6,991,000 |
| Amortization Of Securities | $-2,274,000 | $-757,000 | $-2,331,000 | $-177,000 |
| Depreciation Amortization Depletion | $97,000 | $0 | - | - |
| Depreciation And Amortization | $97,000 | $0 | - | - |
| Net Foreign Currency Exchange Gain Loss | $18,000 | $-42,000 | $-304,000 | $408,000 |
| Net Income From Continuing Operations | $-59,851,000 | $-73,897,000 | $-35,119,000 | $-45,244,000 |
| Asset Impairment Charge | - | $0 | $180,000 | $0 |
Fetched: 2026-06-15